INMB 241220 2.50C (INMB241220C2500) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

INMB241220C2500

Watchlist

1.80
-1.05-36.84%

15min DelayClose Dec 20 16:00 ET

1.80High1.80Low

Intraday

5D
Daily

News

INmune Bio Inc. Completes Repayment of Silicon Valley Bank Debt
GlobeNewswireDec 10 08:00 ET
Inmune Bio Announces Stock Options and Leadership Changes
TipRanksDec 9 16:34 ET
OmniScience and INmune Bio Collaborate to Enhance Clinical Trial Decision-Making With Vivo GenAI Platform
Quiver QuantitativeDec 4 09:12 ET
Express News | Omniscience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer’s Trial With Vivo, a Novel Genai Clinical Trial Control Tower
ReutersDec 4 09:00 ET
OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer's Trial With Vivo, a Novel GenAI Clinical Trial Control Tower
GlobeNewswireDec 4 09:00 ET
INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease
GlobeNewswireNov 13 09:00 ET

Comments

Clintzilla

Nov 27 06:43

$INmune Bio (INMB.US)$ these fucking bios 15% someone loading em up lol

Trytosaveabit

Nov 13 08:06

Update

$INmune Bio (INMB.US)$ Reuters· 5 mins ago
INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease

Jaguar8

Oct 25 00:20

Put on list. Good PR re myelination study.

$INmune Bio (INMB.US)$

Trytosaveabit

Oct 24 14:05

News

$INmune Bio (INMB.US)$ INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination
1 MINUTE AGO, 3:03 PM EDT
VIA GLOBENEWSWIRE
INMB
SHARE
Data from Animal Model Study Demonstrate XPro™ converts microglia from a demyelinating cell to a remyelinating cell
Multi-year study published has implications for many CNS diseases including Alzheimer's

Jaguar8

Oct 24 14:03

NEWS

$INmune Bio (INMB.US)$
INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination
INmune Bio (NASDAQ: INMB) announces publication in Cell Reports demonstrating XPro™'s ability to promote remyelination in demyelinating disease animal models. The study, led by Dr. Leslie Probert at Hellenic Pasteur Institute, shows that XPro1595 converts microglia from damaging to reparative cells by blocking soluble TNF. This research has implications for treating various ...